Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

508 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
BRUIN MCL-321: phase III study of pirtobrutinib versus investigator choice of BTK inhibitor in BTK inhibitor naive mantle cell lymphoma.
Eyre TA, Shah NN, Dreyling M, Jurczak W, Wang Y, Cheah CY, Song Y, Gandhi M, Chay C, Sharman J, Andorsky DJ, Messersmith HM, Ruppert AS, Muthig VA, Ito R, Wang ML. Eyre TA, et al. Among authors: sharman j. Future Oncol. 2022 Nov;18(36):3961-3969. doi: 10.2217/fon-2022-0976. Epub 2022 Nov 15. Future Oncol. 2022. PMID: 36377973 Free article.
Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma.
Connors JM, Jurczak W, Straus DJ, Ansell SM, Kim WS, Gallamini A, Younes A, Alekseev S, Illés Á, Picardi M, Lech-Maranda E, Oki Y, Feldman T, Smolewski P, Savage KJ, Bartlett NL, Walewski J, Chen R, Ramchandren R, Zinzani PL, Cunningham D, Rosta A, Josephson NC, Song E, Sachs J, Liu R, Jolin HA, Huebner D, Radford J; ECHELON-1 Study Group. Connors JM, et al. N Engl J Med. 2018 Jan 25;378(4):331-344. doi: 10.1056/NEJMoa1708984. Epub 2017 Dec 10. N Engl J Med. 2018. PMID: 29224502 Free PMC article. Clinical Trial.
Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial.
Sharman JP, Egyed M, Jurczak W, Skarbnik A, Pagel JM, Flinn IW, Kamdar M, Munir T, Walewska R, Corbett G, Fogliatto LM, Herishanu Y, Banerji V, Coutre S, Follows G, Walker P, Karlsson K, Ghia P, Janssens A, Cymbalista F, Woyach JA, Salles G, Wierda WG, Izumi R, Munugalavadla V, Patel P, Wang MH, Wong S, Byrd JC. Sharman JP, et al. Lancet. 2020 Apr 18;395(10232):1278-1291. doi: 10.1016/S0140-6736(20)30262-2. Lancet. 2020. PMID: 32305093 Free PMC article. Clinical Trial.
Umbralisib, a Dual PI3Kδ/CK1ε Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma.
Fowler NH, Samaniego F, Jurczak W, Ghosh N, Derenzini E, Reeves JA, Knopińska-Posłuszny W, Cheah CY, Phillips T, Lech-Maranda E, Cheson BD, Caimi PF, Grosicki S, Leslie LA, Chavez JC, Fonseca G, Babu S, Hodson DJ, Shao SH, Burke JM, Sharman JP, Law JY, Pagel JM, Miskin HP, Sportelli P, O'Connor OA, Weiss MS, Zinzani PL. Fowler NH, et al. Among authors: sharman jp. J Clin Oncol. 2021 May 20;39(15):1609-1618. doi: 10.1200/JCO.20.03433. Epub 2021 Mar 8. J Clin Oncol. 2021. PMID: 33683917 Free PMC article. Clinical Trial.
Pooled analysis of safety data from clinical trials evaluating acalabrutinib monotherapy in mature B-cell malignancies.
Furman RR, Byrd JC, Owen RG, O'Brien SM, Brown JR, Hillmen P, Stephens DM, Chernyukhin N, Lezhava T, Hamdy AM, Izumi R, Patel P, Baek M, Christian B, Dyer MJS, Streetly MJ, Sun C, Rule S, Wang M, Ghia P, Jurczak W, Pagel JM, Sharman JP. Furman RR, et al. Among authors: sharman jp. Leukemia. 2021 Nov;35(11):3201-3211. doi: 10.1038/s41375-021-01252-y. Epub 2021 Apr 27. Leukemia. 2021. PMID: 33907299
Integrated safety analysis of umbralisib, a dual PI3Kδ/CK1ε inhibitor, in relapsed/refractory lymphoid malignancies.
Davids MS, O'Connor OA, Jurczak W, Samaniego F, Fenske TS, Zinzani PL, Patel MR, Ghosh N, Cheson BD, Derenzini E, Brander DM, Reeves JA, Knopińska-Posłuszny W, Allan JN, Phillips T, Caimi PF, Lech-Maranda E, Burke JM, Agajanian R, Pettengell R, Leslie LA, Cheah CY, Fonseca G, Essell J, Chavez JC, Pagel JM, Sharman JP, Hsu Y, Miskin HP, Sportelli P, Weiss MS, Flinn IW. Davids MS, et al. Among authors: sharman jp. Blood Adv. 2021 Dec 14;5(23):5332-5343. doi: 10.1182/bloodadvances.2021005132. Blood Adv. 2021. PMID: 34547767 Free PMC article. Clinical Trial.
Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients.
Brown JR, Byrd JC, Ghia P, Sharman JP, Hillmen P, Stephens DM, Sun C, Jurczak W, Pagel JM, Ferrajoli A, Patel P, Tao L, Kuptsova-Clarkson N, Moslehi J, Furman RR. Brown JR, et al. Among authors: sharman jp. Haematologica. 2022 Jun 1;107(6):1335-1346. doi: 10.3324/haematol.2021.278901. Haematologica. 2022. PMID: 34587719 Free PMC article.
508 results